Quansys Biosciences & Allegheny Health Network develop a novel 4-plex for use in the diagnosis of Esophageal Cancer
Logan, UT, September 18, 2014—Quansys Biosciences and Allegheny Health Network have collaborated in the development of a novel 4-plex panel of biomarkers to be used in the early diagnosis of esophageal cancer. Esophageal Cancer is a growing disease that although rare, often has deadly outcomes.
Blair Jobe, MD, a surgical oncologist and Director of Allegheny Health Network’s Esophageal and Thoracic Institute, investigated four potential biomarkers associated with esophageal cancer. This panel, called B-AMP, (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9) showed clinical significance in the early diagnosis of Gastroesophageal Reflux Disease, Barrett’s Esophagus, Dysplasia and Esophageal Cancer. Dr. Jobe’s findings were recently published in Cancer, a journal of the American Cancer Society.
Quansys incorporated the clinical specifications necessary to ensure both accurate and precise detection of these four biomarkers. Utilizing the Q-Plex Technology, all four biomarkers were developed to be tested simultaneously in the bottom a single well of a 96-well plate. This methodology allows for efficient sample consumption, ease of use and high quality results.
“The Q-Plex Technology leverages the power of simultaneous detection of multiple biomarkers and ease of use to provide the protein signature necessary for clinical evaluation. In this project, we built each of the four assays to clinical standards allowing for multi-analyte detection,” said Matt Groll, General Manager at Quansys Biosciences.
“This discovery represents a major step forward in not only early detection but also the management of esophageal cancer,” said Dr. Jobe. The test is already being used at Allegheny Health Network in a clinical trial setting to monitor the course of esophageal cancer, providing physicians with guidance on response to therapy or early notification of a recurrence and allowing them to pursue different or more aggressive therapies, if necessary.
About Quansys Biosciences Inc.
Quansys Biosciences is dedicated to the development and manufacture of multiplexed assays for protein quantification. Quansys Biosciences Q-Plex Array Technology aids researchers in better understanding of disease. The Q-Plex Technology includes multiplex and singleplex assays built to maximize the quantity and quality of data from biological samples. To support its multiplex assays Quansys also provides the Q-View Imaging system consisting of: Q-View Software, a user friendly software package that enables the acquisition and analysis of large amounts of multiplex data and the Q-View Imager, a high resolution imaging system used to capture chemiluminescent assays. Quansys Biosciences was founded in 2005 as a Spendlove Research Foundation company.
About the Allegheny Health Network:
Allegheny Health Network is an integrated healthcare delivery system serving the Western Pennsylvania region. The Network is comprised of eight hospitals, including its flagship academic medical center Allegheny General Hospital, Allegheny Valley Hospital, Canonsburg Hospital, Forbes Hospital, Jefferson Hospital, Saint Vincent Hospital, Westfield Memorial Hospital and West Penn Hospital; the Allegheny-Singer Research Institute; Health + Wellness Pavilions; and a healthcare group purchasing organization. The Network employs approximately 17,000 people, including more than 2,100 physicians on its medical staff. The Network also serves as a clinical campus for both Temple University School of Medicine and Drexel University College of Medicine.
To learn more about how Quansys Biosciences can provide the value of the Q-Plex Technology to your research studies, contact Nick Smith, the company’s Sales Manager at email@example.com or